SCHEMBL110832

SCHEMBL110832

NCc1cccc(CN2CCCC2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 2/20 1.00
NCF1 P14598 2/20 0.72
SMN1; SMN2 Q16637 3/20 0.61
ALDH1A1 P00352 2/20 0.61
TDP1 Q9NUW8 1/20 0.61
KDM4E B2RXH2 1/20 0.56
GAA P10253 1/20 0.56
CYP2D6 P10635 2/20 0.54
CYP2C9 P11712 1/20 0.54
HIF1A Q16665 1/20 0.54
CA2 P00918 1/20 0.53
CHKA P35790 1/20 0.53
HRH3 Q9Y5N1 3/20 0.52
CYP2C19 P33261 1/20 0.52
MBTD1 Q05BQ5 1/20 0.49
TP53BP1 Q12888 1/20 0.49
L3MBTL3 Q96JM7 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 1/20 0.49
CHRNB2 P17787 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL111526 0.98 PRMT6 (0.96) PRMT6NCF1SMN1; SMN2ALDH1A1TDP1
SCHEMBL30364132 0.96 PRMT6 (0.93) PRMT6NCF1SMN1; SMN2ALDH1A1TDP1
SCHEMBL11192726 0.88 PRMT6 (0.78) PRMT6SMN1; SMN2ALDH1A1TDP1KDM4E
SCHEMBL11339852 0.88 PRMT6 (0.78) PRMT6SMN1; SMN2ALDH1A1TDP1KDM4E
SCHEMBL10718493 0.85 PRMT6 (0.74) PRMT6NCF1SMN1; SMN2ALDH1A1TDP1
Benzylamine SCHEMBL16584747 0.85 PRMT6 (0.73) PRMT6NCF1SMN1; SMN2ALDH1A1TDP1
SCHEMBL12613628 0.84 PRMT6 (0.73) PRMT6NCF1SMN1; SMN2ALDH1A1TDP1
SCHEMBL20968785 0.84 PRMT6 (0.72) PRMT6NCF1SMN1; SMN2ALDH1A1TDP1
SCHEMBL110388 0.84 NCF1 (1.00) PRMT6NCF1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL21799527 0.84 PRMT6 (0.72) PRMT6NCF1ALDH1A1TDP1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10045736-A None JP disclosed
US-12569566-B2 Compositions containing, methods and uses of antibody-TLR agonist conjugates AMBRX, INC. (US) 2026-03-10 US disclosed
CN-119455003-A Compositions, methods and uses comprising antibody-TLR agonist conjugates AMBRX公司 2025-02-18 CN disclosed
CN-119455004-A Compositions, methods and uses comprising antibody-TLR agonist conjugates AMBRX公司 2025-02-18 CN disclosed
CN-113660957-B Compositions, methods and uses comprising antibody-TLR agonist conjugates AMBRX公司 2024-12-13 CN disclosed
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections GILEAD SCIENCES, INC. (US) 2024-07-30 US disclosed
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-05-09 US disclosed
CN-117736210-A Aromatic heterocyclic compound, and preparation method and application thereof 上海翊石医药科技有限公司 2024-03-22 CN disclosed
EP-3848375-B1 METHODS OF PREPARING INTERMEDIATES FOR TOLL-LIKE RECEPTOR MODULATORS GILEAD SCIENCES INC (US) 2023-12-27 EP disclosed
CN-114805341-B Aromatic heterocyclic compound, and preparation method and application thereof 上海翊石医药科技有限公司 2023-12-08 CN disclosed
EP-1131288-A1 PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2001-09-12 EP disclosed
EP-1116716-A1 Piperidine and piperazine compounds for use in the treatment of Alzheimer Eisai Co., Ltd. (JP) 2001-07-18 EP disclosed
WO-2000031032-A1 PYRROLIDINE DERIVATIVES-CCR-3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2000-06-02 WO disclosed
JP-H1045736-A META-XYLYLENEDIAMINE DERIVATIVE MITSUBISHI GAS CHEM CO INC 1998-02-17 JP disclosed
EP-0742207-A1 2-(Indan-1-one-2-yl-alkyl)-1-phenylalkyl-piperidines and processes for their preparation Eisai Co., Ltd. (JP) 1996-11-13 EP disclosed
EP-0673927-A1 4-[2-indanyl-1-one]alkylpiperidines as anticholinergic agents Eisai Co., Ltd. (JP) 1995-09-27 EP disclosed
EP-0579263-A1 1,4-Substituted piperidines as acetylchozinesterase inhibitors and their use for the treatment of Alzheimer's disease Eisai Co., Ltd. (JP) 1994-01-19 EP disclosed
US-5100901-A Treatment of Alzheimer*s disease EISAI CO., LTD. (JP) 1992-03-31 US disclosed
US-4895841-A Cyclic amine compounds with activity against acetylcholinesterase EISAI CO., LTD. (JP) 1990-01-23 US disclosed
EP-0296560-A2 1,4-Substituted piperidines as acetylcholinesterase inhibitors and their use for the treatment of Alzheimer's disease Eisai Co., Ltd. (JP) 1988-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF TLR7, TLR1, TLR8 PRMT6 4449/4885NCF1 600/4885SMN1; SMN2 3760/4885
US-12049461-B2 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections NR3C1, NR3C2, NR4A1 PRMT6 757/4885NCF1 1648/4885SMN1; SMN2 3900/4885
US-12569566-B2 Compositions containing, methods and uses of antibody-TLR agonist conjugates TLR3, TLR2, TLR1 PRMT6 1595/4885NCF1 2424/4885SMN1; SMN2 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.